Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma

Table 1

Demographic and clinical data.

Characteristic	PA group; n=60	Control group; n=64	p value
Gender
Males, n (%)	22 (36.7)	14 (21.9)	0.070
Females, n (%)	38 (63.3)	50 (78.1)
Age at onset (years) (min/max/median)	24/83/50	19/82/55	0.465
Symptoms:		NA	-
(1) Visual disturbances (decreased visual acuity, visual field defects, etc.)	39
(2) Headache	25
(3) Weakness	9
(4) Acromegaly (exaggerated growth of the hands and feet, with thick fingers and toes, enlargement of the lower lip and nose, etc.)	8
(5) Prolactinoma symptoms (disruption of menstrual cycle, milk production unrelated to pregnancy or nursing, etc.)	10
Recurrence:		NA	-
Absent/present	51/9
Invasiveness:		NA	-
Invasive/noninvasive	25/35
Surgery/conservative treatment	55/5	NA	-